Epigenetics and In Silico Transcriptome Analysis of Pediatric Acute Myeloid Leukemia

Area of Science:

• Pediatric Hematology/Oncology
• Cancer Genomics
• Epigenetics

Background:

• Pediatric acute myeloid leukemia (AML) is a diverse childhood cancer with frequent relapses and poor outcomes for high-risk groups.
• Pediatric AML exhibits unique genetic mutations and epigenetic dysregulation, differing from adult forms.
• Current treatments face challenges due to disease heterogeneity and relapse rates.

Purpose of the Study:

• To review the molecular and epigenetic landscape of pediatric AML.
• To highlight the role of in silico transcriptomic analysis in identifying disease drivers.
• To explore the potential of epigenetic therapies for improved pediatric AML treatment.

Main Methods:

• In silico transcriptomic analysis integrating gene expression and epigenetic data.
• Computational RNA-seq pipelines and pathway analyses.
• Multi-omics approaches (transcriptomic, methylomic, chromatin accessibility).

Main Results:

• Identification of distinct genetic mutations (e.g., FLT3-ITD, NPM1, KMT2A) and epigenetic alterations in pediatric AML.
• Uncovering key epigenetic regulators (DNMT3A, TET2, HDACs) as potential therapeutic targets.
• Demonstration of multi-omics utility in defining biomarkers for diagnosis, prognosis, and treatment response.

Conclusions:

• In silico transcriptomic analysis is crucial for understanding pediatric AML mechanisms.
• Epigenetic dysregulation presents significant therapeutic opportunities.
• Precision-based epigenetic therapies guided by molecular insights can enhance outcomes for children with AML.